CoChat
Sign Up
Cited by 11Ovarian cancer diagnosis and treatmentInflammatory Biomarkers in Disease PrognosisBRCA gene mutations in cancer

Early onset neutropenia: a useful predictor of chemosensitivity and favorable prognosis in patients with serous ovarian cancer

Open access
He, Yijing, Li, Ting, Liu, Jue, Ou, Qiong, Zhou, Junlin·2020·BMC Cancer
DOI 10.1186/s12885-020-6609-xPMC PMC7014607
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-associated deaths and a majority of its histological type is manifested as serous ovarian cancer (SOC). In this study, we investigated whether the timing of onset of chemotherapy-induced neutropenia (CIN) is related to chemotherapeutic response and disease outcome of SOC. METHODS: One hundred sixty-nine primary SOC patients receiving six doses of carboplatin plus paclitaxel adjuvant chemotherapy following cytoreductive surgery were retrospectively included in this research. CIN was grouped as early onset and late onset neutropenia depending on the timing of development. Development of CIN prior to or with administration of 3rd cycle of chemotherapy was listed as early onset neutropenia, while those CIN due to later stage chemotherapy were grouped into non-early type. The relevance of time of CIN onset with the clinical characteristics, chemotherapeutic response, progression free survival (PFS) and overall survival (OS) were determined and analyzed by using Kaplan-Meier curves, Logistic regression method, Cox proportional hazards models, and Chi-square tests. RESULTS: The age distribution of the patients was between 27 to 77 years. Fifty years was the median. No statistical significances of difference in age, FIGO stage, histological grade, tumor residual and lymph node invasion, as well as CA125 level in each CIN group were found (all P>0.05). The patients from non-early onset group showed higher chemoresistance rates (78.33%) compared to those from early onset group (9.17%). Additionally, patients in early onset group showed improved median PFS (23 vs. 9 months; P<0.001) and median OS (55 vs.24 months; P<0.001). CONCLUSIONS: Early onset neutropenia may be potentially used as a potential indicator for chemosensitivity and favorable prognosis of SOC in patients who underwent six cycles of carboplatin plus paclitaxel adjuvant chemotherapy following primary cytoreductive surgery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-020-6609-x

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
He, Y., Li, T., Liu, J., Ou, Q., & Zhou, J.
Affiliations
  • University of South China (CN)
  • First Affiliated Hospital of University of South China (CN)
Corresponding author
Zhou, Junlin
ORCID
Venue
BMC Cancer
Publisher
Springer Science and Business Media LLC
Published
2020-02-12
Volume
20
Issue
1
Pages
116-116
ISSN
1471-2407 (ISSN-L)
DOI
10.1186/s12885-020-6609-x
PMC
PMC7014607
OpenAlex
W3009219034
Cited by
11
References
30
Citations by year
2026: 1 · 2025: 2 · 2023: 3 · 2022: 2 · 2021: 3
FWCI
1.76
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
serous ovarian cancer, chemotherapy-induced neutropenia, carboplatin, paclitaxel, adjuvant chemotherapy, chemosensitivity, chemoresistance, progression-free survival, overall survival, prognostic factors, cytoreductive surgery
MeSH terms
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Neutropenia, Ovarian Neoplasms, Prognosis, Retrospective Studies, Cystadenocarcinoma, Serous, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review